There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ICCM is 28.72M and currently, short sellers hold a 0.74% ratio of that float. The average trading volume of ICCM on June 25, 2025 was 240.55K shares.
ICCM) stock’s latest price update
Icecure Medical Ltd (NASDAQ: ICCM)’s stock price has gone decline by -1.72 in comparison to its previous close of 0.99, however, the company has experienced a 3.19% increase in its stock price over the last five trading days. prnewswire.com reported 2025-06-25 that CAESAREA, Israel, June 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the “Rights Offering”) to all holders of record of the Company’s ordinary shares as of 5:00 p.m.
ICCM’s Market Performance
Icecure Medical Ltd (ICCM) has seen a 3.19% rise in stock performance for the week, with a -8.22% decline in the past month and a -17.55% plunge in the past quarter. The volatility ratio for the week is 4.44%, and the volatility levels for the past 30 days are at 3.59% for ICCM. The simple moving average for the last 20 days is -2.55% for ICCM’s stock, with a simple moving average of -3.26% for the last 200 days.
ICCM Trading at -8.06% from the 50-Day Moving Average
After a stumble in the market that brought ICCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.39% of loss for the given period.
Stock Fundamentals for ICCM
Current profitability levels for the company are sitting at:
- -4.77 for the present operating margin
- 0.44 for the gross margin
The net margin for Icecure Medical Ltd stands at -4.65. The total capital return value is set at -2.22. Equity return is now at value -173.47, with -112.66 for asset returns.
Based on Icecure Medical Ltd (ICCM), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -27.31.
Currently, EBITDA for the company is -15.36 million with net debt to EBITDA at 0.46. When we switch over and look at the enterprise to sales, we see a ratio of 14.9. The receivables turnover for the company is 14.86for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.89.
Conclusion
In conclusion, Icecure Medical Ltd (ICCM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
